Name | ABT-072 |
---|---|
Synonyms |
Methanesulfonamide, N-[4-[(E)-2-[5-(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)-3-(1,1-dimethylethyl)-2-methoxyphenyl]ethenyl]phenyl]-
N-(4-{(E)-2-[5-(2,4-Dioxo-3,4-dihydro-1(2H)-pyrimidinyl)-2-methoxy-3-(2-methyl-2-propanyl)phenyl]vinyl}phenyl)methanesulfonamide PSQ4R5K1QI |
Description | ABT-072 is a nonnucleoside NS5B polymerase inhibitor and a candidate drug evaluated for treatment of hepatitis C virus. |
---|---|
Related Catalog | |
In Vitro | ABT-072 inhibits non-nucleoside NS5B polymerase, and yields antiviral effects[1]. |
Cell Assay | To determine compound efficacy, HCV replicon cells are plated at a density of 104 per well in 96-well plates in DMEM media containing 10% FBS. Following incubation overnight, compounds serially diluted in DMSO, or DMSO alone, are added to individual wells to a final DMSO concentration of 0.5%. Cell plates are then incubated at 37°C. for 3 days prior to assaying for cytotoxicity and HCV inhibition. Cell viability is measured using an Alamar Blue assay and CC50 values are calculated using the median effect equation. |
References |
[1]. Min Gao, et al. Combinations of Hepatitis C Virus Inhibitors. US 20120196794 A1 |
Density | 1.3±0.1 g/cm3 |
---|---|
Molecular Formula | C24H27N3O5S |
Molecular Weight | 469.553 |
Exact Mass | 469.167145 |
LogP | 3.64 |
Index of Refraction | 1.625 |
Storage condition | 2-8℃ |